On January 9, Beijing time, the State Council’s Joint Prevention and Control Mechanism held a press conference. Zeng Yixin, deputy director of the National Health Commission, said that so far, my country has carried out nearly 9 million doses of new coronavirus vaccination, proving that my country's new coronavirus vaccine has good safety. In the next step, we will comprehensively and orderly promote the vaccination of high-transmission groups, high-risk groups and the general population, and implement free vaccination for all. Li Tao, deputy director of the National Medical Security Administration, said that the cost of vaccination will be borne by the medical insurance fund and finance, and residents will not bear the cost.

Sinopharm China Biosciences has started the large-scale production of the new crown vaccine. Each dose of vaccine has an electronic ID card that traces the flow of the vaccine throughout. Where the vaccine reaches and who is vaccinated will be recorded.

It is understood that the new crown vaccine packaging is divided into light inspection, rotary rod labeling, boxing, weighing, and coding systems to ensure the quality and safety of the vaccine.

Yang Xiaoming, Chairman of Sinopharm Group China Biotechnology, introduced that the regulatory code is equivalent to the "electronic ID card" of vaccines, which is divided into three levels: each vaccine is individually coded, every 10 vaccines is composed of a medium package code, and contains multiple medium packages The large package and then code.

Through the supervision code, you can check whether the vaccine production, warehousing, storage, delivery, transportation and other processes meet the standards, and track the person receiving the injection.

The size of my country's new crown vaccine market may be nearly 100 billion

China Securities Investment said that at this stage, orders for the new crown vaccine have been placed. According to the order volume, the country’s penetration rate is calculated. The United States, the United Kingdom, the European Union of four countries and Japan are respectively 100%, 100%, 65% and 100%. Taking into account the epidemic situation in my country Stable, but the world is still in the pandemic stage and my country is accompanied by repeated regional epidemics. It is estimated that the penetration rate of my country's new crown vaccine is generally assumed to be 60%, and the corresponding market size is about 84 billion yuan.

According to the agency, according to my country’s current clinical trial phase of the new crown vaccine project, according to the existing design capacity limit is about 1.8 billion doses, which can meet the demand of 900 million people. Considering the time required for the release of production capacity of some enterprises, it will be available in a short time. There are still gaps in the supply of new crown vaccine projects to the domestic and developing markets.

According to CCTV news, as of 6:00 today, tianwen-1 Mars probe has been in orbit for 163 days, with a flight mileage of more than 400 million kilometers, about 130 million kilometers from the earth and 8.3 million kilometers from Mars.

China Aerospace Group official said that tianwen-1 Mars probe has a stable attitude, and will implement near fire braking in more than one month as planned, enter the annular fire orbit, and be ready to land on Mars.

Tianwen-1 mission is the first step of China's independent interplanetary exploration. It will realize the "orbit, landing and patrol" of Mars through a single launch, that is, Mars orbit, Mars landing and fire surface patrol.

The total weight of tianwen-1 is about 5 tons. It is composed of a orbiter and a landing Rover. The landing Rover mainly includes an entry module and a Mars rover. At present, the orbiter has completed the third on orbit self-test, and all systems are working normally.

Five vaccines in China enter phase III clinical trials

At the press conference, Chen Shifei, deputy director of the State Drug Administration, said that Sinopharm's China Bio new crown inactivated vaccine had been approved by the State Drug Administration for conditional marketing. The existing data show that the protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, meeting the relevant standards of who and SFDA. In the future, the persistence and protective effect of the vaccine should be observed continuously.

In addition, Xu Nanping, Vice Minister of the Ministry of science and technology, said that so far, 14 vaccines from five technical routes have entered clinical trials in China, of which five vaccines from three technical routes have entered phase III clinical trials.

Grant of new vaccines in Beijing and Hubei
At the press conference, Chen Shifei said that the drug regulatory and inspection institutions in Beijing and Hubei Province have been awarded the task of issuing the new crown vaccine in batches. In accordance with relevant regulations and administrative measures, the batch issuing agency will strictly audit and inspect each batch of vaccines to ensure that each vaccine is qualified.

Does the new coronavirus mutation affect the efficacy of the vaccine?

At the press conference, Xu Nanping said that the scientific research team has held many meetings, and experts believe that there is no evidence that the new coronavirus mutation will have a substantial impact on the use of the vaccine, but it needs high attention.

What is the price of the approved vaccine?

Zeng Yixin, deputy director of the National Health Commission, said that the basic attribute of the new coronavirus vaccine is public goods, and the price will change according to the scale of use, but one major premise is definitely to provide free for all.

Over 3 million doses of the vaccine have been given to key population in China, with good safety
At the press conference, Zeng Yixin introduced the vaccination work of key groups of Xinguan vaccine. He said that China's vaccine research and development has always been the first in the world
Since the official launch of vaccination work for key population on December 15, the cumulative number of inoculations has exceeded 3 million.

The results of vaccination fully proved that the safety of vaccine in China was good, a certain proportion of adverse reactions occurred, and the total incidence was close to that of conventional inactivated vaccine.

The main performance is local pain, induration, mild fever rate is less than 0.1%, allergy and other serious situation is two parts per million, these situations after timely treatment are very good treatment.

Next, we will comprehensively promote the vaccination of the elderly and people with basic diseases, and then carry out the vaccination of other ordinary people. In the future, all the eligible people will be able to "receive as much as possible.".

Sinopharm China Biological New Crown inactivated vaccine has been approved by the State Food and Drug Administration for conditional listing

Vaccine research and development will never "rush" for the first place

At the press conference, Zheng Zhongwei, head of the working group of new crown vaccine research and development, said that the vaccine research and development process is a race against the virus, but we fully respect the scientific laws and principles of vaccine research and development.
China is the first to carry out clinical trials, and also the first to carry out phase III clinical trials. However, due to the good control of the epidemic situation in our country, we carry out clinical trials abroad, strictly abide by the relevant rules in the process of clinical trials, and will never "rush" for the first place.

Turkish health minister Kejia said on the evening of the 24th that Turkey has confirmed that the new inactivated vaccine developed by China's Beijing Kexing zhongweisheng Technology Co., Ltd. is effective and safe for the Turkish people.

Kejia said at a news conference that night that the preliminary analysis of the data of volunteers who voluntarily vaccinated with kexingxinguan vaccine in Turkey showed that the effectiveness of kexingxinguan vaccine reached 91.25%, and no serious side effects were found during the clinical trial. China has approved the export of vaccines to Turkey. If all goes well, the first 3 million doses of vaccines from China will arrive in Turkey in the near future.

Kejia also said that in the first stage, 9 million people will be vaccinated, mainly for high-risk groups such as medical staff.

Data released on the website of Turkey's Ministry of health on the 25th showed that 201104 people in Turkey were tested for new coronavirus on the same day, with 17543 newly diagnosed cases, of which 3199 were symptomatic infections, with a total of 2118255 confirmed cases; 256 new deaths, with a total of 19371 deaths; 1970803 cured cases.

In addition to Turkey, the Brazilian health department also disclosed the effectiveness of China's Kexing vaccine, which met the international standards. Kovas, director of Brazil's Butantan Research Institute, said that the Chinese vaccine is the safest currently tested in Brazil, and it has given the Brazilian people light.